HGSI Gets Slightly Increased Buyout Bid, Accepts GSK Offer Of $3.6 Billion
This article was originally published in The Pink Sheet Daily
After three months of battling, with lupus drug Benlysta still struggling, Human Genome Sciences accepted a modestly increased sales offer from partner GlaxoSmithKline.
You may also be interested in...
10 Drug Launch Flops Of The Decade
The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.
Benlysta Is Niche, But Growing, So GSK's Not Giving Up On Lupus
Sales of the BLyS inhibitor disappointed at launch, but the franchise is growing double-digits and now a new, more convenient subcutaneous formula will provide another growth opportunity.
BARDA Signs Biodefense Contracts With GSK And Soligenix
Under a pair of agreements announced Sept. 19, the HHS unit will stockpile 60,000 doses of GSK’s inhalation anthrax treatment and will fund development of a treatment for GI acute radiation syndrome by New Jersey biotech Soligenix.